| Company/Division name | Sharp Services |
| Parent company | United Drug Group |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2025 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 100 |
| Country(ies) from which reshored: | Ireland |
| City reshored to: | Allentown |
| State(s) reshored to: | PA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals, Medical Equipment & Supplies |
| Product(s) reshored | biopharmaceuticals, pre-filled syringes |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Higher productivity |
